Benitec Biopharma Inc.
BNTC
$12.37
-$0.63-4.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.43% | 17.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.53% | 36.46% | |||
| Operating Income | -1.53% | -36.46% | |||
| Income Before Tax | -0.83% | -32.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.83% | -32.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.83% | -32.04% | |||
| EBIT | -1.53% | -36.46% | |||
| EBITDA | -1.53% | -36.50% | |||
| EPS Basic | 6.14% | -19.27% | |||
| Normalized Basic EPS | 6.15% | -19.27% | |||
| EPS Diluted | 6.14% | -19.27% | |||
| Normalized Diluted EPS | 6.15% | -19.27% | |||
| Average Basic Shares Outstanding | 7.43% | 10.72% | |||
| Average Diluted Shares Outstanding | 7.43% | 10.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||